Pfizer (PFE) stock, Alnylam (ALNY) stock and BridgeBio (BBIO) stock jump after a trial setback for an ATTE-CM drug from Astra ...
AstraZeneca reported a phase III failure for its ATTR-CM drug Wainua, shifting attention to competitors in this rare heart ...
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...
In recent days, Alnylam Pharmaceuticals has benefited from the late-stage failure of AstraZeneca and Ionis’s competing ...
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive ...
Ionis Pharmaceuticals Inc. IONS and partner AstraZeneca Plc AZN said on Thursday that their Phase 3 CARDIO-TTRansform study ...
Clinical Trials Arena on MSN
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure
AstraZeneca and Ionis both saw their stocks take a hit on 9 July following the ATTR-CM trial failure.
The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent ...
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are ...
(Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results